Coronary Artery Disease (CAD) - Disease Information

Overview

Coronary Artery Disease (CAD) is a condition characterized by atherosclerotic plaque accumulation in the coronary arteries, leading to impaired blood flow to the myocardium. It represents the most common type of heart disease and the leading cause of death worldwide.

Global Burden: CAD affects approximately 126 million people globally (1.72% of world population) and causes about 9 million deaths annually. The prevalence increases with age, affecting 6.7% of adults aged 40-59 and 19.8% of those aged 60-79. Despite advances in treatment, CAD remains the single largest cause of mortality in developed countries.

Classification & Spectrum

Clinical Spectrum of CAD:

Condition	Prevalence	Key Features	Mortality Risk
Stable Angina	40-50%	Predictable chest pain with exertion, relieved by rest	2-3% annual
Unstable Angina	20-25%	Resting pain, progressive symptoms, new onset	5-10% at 6 months
NSTEMI	15-20%	Positive biomarkers, no ST elevation	6-8% in-hospital
STEMI	10-15%	ST elevation, transmural infarction	7-12% in-hospital
Silent Ischemia	10-15%	Asymptomatic, detected incidentally	Similar to symptomatic

Anatomic Classification (SYNTAX Score):

SYNTAX Score	Complexity	PCI Success	CABG Preference
0-22	Low	High	PCI preferred
23-32	Intermediate	Moderate	Individualized
≥33	High	Low	CABG preferred

Pathophysiology & Risk Factors

Atherosclerosis Development Stages:

Endothelial Dysfunction: Initial injury and inflammation
Fatty Streak Formation: Lipid accumulation in intima
Fibrous Plaque: Smooth muscle proliferation and collagen deposition
Complicated Lesion: Plaque rupture, thrombosis, calcification

Major Modifiable Risk Factors:

Risk Factor	Population Attributable Risk	Relative Risk	Intervention Impact
Dyslipidemia	45-50%	2.5-3.5x	25-35% risk reduction with statins
Hypertension	25-30%	2.0-3.0x	20-25% risk reduction with control
Smoking	20-25%	2.5-4.0x	50% risk reduction after 1 year cessation
Diabetes Mellitus	10-15%	2.0-4.0x	15-20% risk reduction with good control
Obesity	10-15%	1.5-2.5x	35-45% risk reduction with 10% weight loss

Non-modifiable Risk Factors:

Age: Risk doubles every decade after age 45
Male Gender: 2-3x higher risk until age 70
Family History: 1.5-2.0x risk with first-degree relative
Ethnicity: Higher prevalence in South Asians, African Americans

Clinical Presentation

Classic Angina Symptoms:

Location: Substernal, may radiate to arms, neck, jaw
Quality: Pressure, squeezing, heaviness, burning
Duration: 2-10 minutes, rarely >20 minutes
Precipitants: Exertion, emotion, cold, heavy meals
Relief: Rest, nitroglycerin

Atypical Presentations (More Common in):

Population	Atypical Symptoms	Frequency
Women	Fatigue, shortness of breath, nausea	40-60%
Elderly	Confusion, syncope, weakness	50-70%
Diabetics	Silent ischemia, dyspnea only	25-40%
Post-CABG/PCI	Vague discomfort, atypical patterns	30-50%

Acute Coronary Syndrome Red Flags: Chest pain at rest >20 minutes, associated nausea/vomiting, diaphoresis, syncope, hemodynamic instability, new heart failure symptoms. Requires immediate medical attention.

Diagnosis & Investigations

Initial Evaluation (Stable CAD):

History: Characterize symptoms, risk factors, functional limitation
Physical Exam: Often normal, look for signs of complications
ECG: May show Q waves, ST-T changes, conduction abnormalities
Basic Labs: Lipid profile, glucose, creatinine, cardiac biomarkers if acute

Diagnostic Testing Modalities:

Test	Sensitivity	Specificity	Indications
Exercise ECG	45-50%	85-90%	Initial test in intermediate probability, able to exercise
Stress Echocardiography	80-85%	80-85%	Better for localization, assessment of LV function
Myocardial Perfusion Imaging	85-90%	70-75%	Unable to exercise, prior revascularization
Coronary CTA	95-99%	64-80%	Low-intermediate probability, atypical symptoms
Invasive Angiography	Gold standard	Gold standard	High probability, positive non-invasive test, ACS

Risk Stratification Tools:

Tool	Parameters	Output	Clinical Use
Framingham Risk Score	Age, sex, BP, cholesterol, smoking, diabetes	10-year CVD risk	Primary prevention
ASCVD Risk Calculator	Similar to Framingham, includes race	10-year ASCVD risk	Current US guidelines
Duke Treadmill Score	Exercise duration, ST depression, angina	Mortality risk	Prognosis after stress test

Treatment & Management

Medical Therapy (All Patients):

Medication Class	Examples	Mechanism	Mortality Benefit
Antiplatelets	Aspirin, Clopidogrel, Ticagrelor	Prevent thrombosis	25% reduction
Statins	Atorvastatin, Rosuvastatin	Plaque stabilization, lipid lowering	30% reduction
Beta-blockers	Metoprolol, Bisoprolol, Carvedilol	Reduce myocardial oxygen demand	20-30% reduction
ACE Inhibitors/ARBs	Lisinopril, Ramipril, Valsartan	Vasodilation, anti-remodeling	20-25% reduction
Antianginals	Nitrates, Ranolazine, Ivabradine	Symptom relief, reduce angina	Symptomatic only

Revascularization Strategies:

Modality	Indications	Success Rate	Restenosis Rate
PCI with Stenting	1-2 vessel disease, preserved LV function	95-98%	5-10% (DES) 20-30% (BMS)
CABG	Left main, multivessel disease, diabetes, low EF	98-99%	3-5% per year (vein) 1-2% per year (artery)

Lifestyle Interventions (Class I Recommendations):

Smoking Cessation: Complete abstinence
Mediterranean Diet: Fruits, vegetables, whole grains, fish
Physical Activity: 150 min/week moderate or 75 min/week vigorous
Weight Management: BMI 18.5-24.9 kg/m²
Alcohol Moderation: ≤1 drink/day (women), ≤2 drinks/day (men)

Ayurvedic Treatment

Ayurvedic Perspective:

CAD is understood as Hridroga with predominant Vata and Kapha involvement. The condition represents Rasavaha and Raktavaha Srotas Dushti (impairment of nutrient and blood channels) affecting the heart (Hridaya).

Herbal Formulations:

Arjunarishta: Primary cardiotonic and anti-ischemic formulation
Punarnavadi Guggulu: For associated edema and congestion
Chandraprabha Vati: Comprehensive metabolic support
Triphala Guggulu: For detoxification and lipid management
Hridayarnava Rasa: Specific for cardiac conditions
Pushkaramoolasava: For respiratory symptoms in heart disease

Single Herbs:

Herb	Sanskrit Name	Properties	Specific Benefits for CAD
Arjuna	Arjuna (Terminalia arjuna)	Cardiotonic, hypotensive, anti-ischemic	Improves contractility, reduces angina, antioxidant
Guggulu	Guggulu (Commiphora mukul)	Lipid-lowering, anti-inflammatory, anti-atherogenic	Reduces plaque formation, improves lipid profile
Ashwagandha	Aśvagandhā (Withania somnifera)	Adaptogen, cardiotonic, anti-stress	Reduces stress-induced ischemia, improves exercise tolerance
Garlic	Laśuna (Allium sativum)	Lipid-lowering, antiplatelet, hypotensive	Reduces cholesterol, prevents thrombosis
Turmeric	Haridrā (Curcuma longa)	Anti-inflammatory, antioxidant, anti-atherogenic	Reduces vascular inflammation, plaque stabilization
Ginger	Ārdraka (Zingiber officinale)	Antiplatelet, lipid-lowering, anti-inflammatory	Improves circulation, reduces thrombotic risk
Brahmi	Brahmi (Bacopa monnieri)	Adaptogen, antioxidant, neuro-cardiac protection	Reduces stress, improves endothelial function
Shilajit	Shilājit (Asphaltum)	Rejuvenative, cardiotonic, adaptogen	Improves energy, supports myocardial function

Ayurvedic Procedures:

Virechana (Therapeutic Purgation):
- Eliminates excess Pitta and metabolic toxins
- Reduces inflammation and lipid accumulation
- Contraindicated in unstable CAD, recent MI
Basti (Medicated Enema):
- Balances Vata dosha (primary in heart disease)
- Nourishing Basti for cardiac tissue support
- Improves circulation and nervous system function
Hrid Basti: Specialized local therapy
- Retention of warm medicated oil over chest
- Direct nourishment to heart region
- Improves local circulation and function
Shirodhara: Continuous oil stream on forehead
- Reduces sympathetic overactivity
- Decreases stress and anxiety
- Improves heart rate variability
Udvartana: Herbal powder massage
- Reduces Kapha and Meda (fat tissue)
- Improves circulation and metabolism
- Helpful in obesity-associated CAD

Dietary Recommendations (Ahara):

Recommended Foods:
- Whole grains (barley, oats, wheat)
- Fresh fruits and vegetables (especially leafy greens)
- Lean proteins (moong dal, legumes, fish)
- Healthy fats (ghee, olive oil, nuts in moderation)
- Garlic, onion, ginger, turmeric in cooking
- Herbal teas (arjuna, ginger, cinnamon)
Foods to Avoid:
- Red meat and processed meats
- Fried and fatty foods
- Excess salt and sugar
- Refined carbohydrates
- Full-fat dairy products
- Alcohol and tobacco
Special Recommendations:
- Arjuna bark decoction twice daily
- Garlic preparations (cooked, not raw)
- Triphala for gentle detoxification
- Warm water with honey and lemon
- Regular but light meals

Lifestyle Modifications (Vihara):

Physical Activity:
- Regular moderate exercise (walking, swimming)
- Yoga asanas: Tadasana, Vajrasana, Shavasana, gentle backbends
- Pranayama: Anulom Vilom, Bhramari, Sheetali
- Avoid strenuous exercise during angina episodes
Daily Routine (Dinacharya):
- Early morning waking and elimination
- Regular meal times (avoid heavy meals)
- Adequate rest and sleep (7-8 hours)
- Oil massage with mild oils (sesame, coconut)
Stress Management:
- Regular meditation and mindfulness
- Pranayama and relaxation techniques
- Adequate leisure and recreational activities
- Positive social interactions
Seasonal Regimen (Ritucharya):
- Light diet in summer, warm in winter
- Avoid extreme temperatures
- Regular detoxification in seasonal transitions

Ayurvedic Management Strategy: Comprehensive approach includes Nidana Parivarjana (avoidance of causative factors), Shodhana (purification therapies) for toxin elimination and plaque reduction, Shamana (palliative treatments) for symptom relief and cardiac support, Rasayana (rejuvenation therapies) for myocardial strengthening and prevention of complications, and strict Pathya-Apathya (dietary and lifestyle regulations) for long-term management.

Complications

Acute Complications:

Complication	Frequency	Mortality	Management
Myocardial Infarction	15-20% of CAD patients	5-10% in-hospital	Reperfusion, medical therapy
Heart Failure	20-25% post-MI	10-15% annual	GDMT, device therapy
Arrhythmias	10-15%	Variable	Antiarrhythmics, ablation, ICD
Cardiogenic Shock	5-8% of MI	40-50%	Vasopressors, mechanical support

Chronic Complications:

Progressive Heart Failure: From recurrent ischemia and remodeling
Ventricular Aneurysm: Post-infarction complication
Ischemic Cardiomyopathy: Global LV dysfunction
Sudden Cardiac Death: From ventricular arrhythmias
Refractory Angina: Despite maximal medical therapy

Prognosis

Prognosis varies significantly based on extent of disease, LV function, and risk factor control. With optimal medical therapy, 5-year survival exceeds 90% for stable CAD. Post-MI survival is 75-85% at 5 years with modern management.

Factors Affecting Prognosis:

Factor	Impact on Mortality	Modifiability
LV Ejection Fraction	EF <30%: 15-20% annual mortality	Partially
Number of Diseased Vessels	3-vessel: 2-3x higher risk than 1-vessel	No
Diabetes Mellitus	2-4x higher mortality	Partially
Renal Function	eGFR <30: 3-5x higher mortality	Partially
Medication Adherence	Non-adherence: 50-80% higher mortality	Yes

Long-term Outcomes:

Parameter	1-Year	5-Year	10-Year
Overall Survival	95%	85%	70%
MI-free Survival	90%	75%	60%
Heart Failure-free	85%	70%	55%
Repeat Revascularization	5-10%	15-25%	25-35%

Secondary Prevention

Comprehensive Risk Factor Management:

Intervention	Goal	Relative Risk Reduction
LDL Cholesterol	<70 mg/dL (very high risk) <100 mg/dL (high risk)	22% per 39 mg/dL reduction
Blood Pressure	<130/80 mm Hg	25% with good control
Glycemic Control	HbA1c <7%	15-20% with good control
Smoking Cessation	Complete abstinence	50% after 1 year
Physical Activity	150 min/week moderate	20-30%

Cardiac Rehabilitation Components:

Exercise Training: Supervised, progressive program
Education: Disease management, risk factor control
Counseling: Psychological support, stress management
Nutritional Guidance: Heart-healthy diet planning
Medication Adherence: Education and monitoring

Special Considerations

CAD in Specific Populations:

Population	Special Features	Management Considerations
Women	Atypical symptoms, microvascular disease, later onset	Higher threshold for testing, consider non-obstructive CAD
Diabetics	Multivessel disease, silent ischemia, worse outcomes	More aggressive risk factor control, prefer CABG for multivessel
Elderly	Atypical presentation, comorbidities, frailty	Individualized approach, consider functional status
Chronic Kidney Disease	Accelerated CAD, contrast nephropathy risk	Careful medication dosing, consider non-contrast options

Emergency Situations: Acute chest pain with hemodynamic instability, ST-elevation MI, cardiogenic shock, sustained ventricular arrhythmias, acute heart failure. Require immediate hospital admission and specialized care.

Follow-up & Monitoring

Routine Follow-up Schedule:

Time Period	Frequency	Key Assessments
First 3 months	Monthly	Symptoms, medication tolerance, risk factor control
3-12 months	Every 3 months	Functional status, lipid profile, BP control
After 1 year	Every 6-12 months	Comprehensive risk factor assessment, cardiac testing if indicated

Long-term Monitoring Parameters:

Symptom Assessment: Angina frequency, functional capacity
Risk Factor Control: BP, lipids, glucose, weight
Medication Adherence: Review and optimize regimen
Complication Screening: Heart failure symptoms, arrhythmias
Quality of Life: Physical, emotional, social functioning